Avidity Biosciences, Inc. (RNA) Depreciation and Depletion (2019 - 2025)

Avidity Biosciences' Depreciation and Depletion history spans 7 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 103.25% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $4.2 million, up 52.85%, while the annual FY2025 figure was $4.2 million, 51.3% up from the prior year.
  • Depreciation and Depletion reached $1.5 million in Q4 2025 per RNA's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.5 million in Q4 2025 to a low of $100000.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $552950.0, with a median of $550000.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: changed 0.0% in 2021, then soared 214.0% in 2022.
  • A 5-year view of Depreciation and Depletion shows it stood at $208000.0 in 2021, then surged by 92.31% to $400000.0 in 2022, then surged by 53.5% to $614000.0 in 2023, then rose by 20.2% to $738000.0 in 2024, then soared by 103.25% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Depreciation and Depletion are $1.5 million (Q4 2025), $1.1 million (Q3 2025), and $800000.0 (Q2 2025).